The Dual Role of cGAS-STING Signaling in COVID-19: Implications for Therapy

Since its emergence in late 2019, coronavirus disease 2019 (COVID-19) has rapidly become a global health crisis, with nearly 800 million confirmed cases and 7 million fatalities. The pandemic has had profound effects on public health systems and the global economy. The progression of COVID-19c involves a complex and intricated interplay between the SARS-CoV-2 virus and the host's immune response. The immune system employs both innate and adaptive mechanisms to combat infection. Innate immunity initiates the release of interferons (IFNs) and pro-inflammatory cytokines, while the adaptive immune response involves CD4+ Th lymphocytes, B lymphocytes, and CD8+ Tc cells. Pathogen-associated molecular patterns (PAMPS) and damage- associated molecular patterns (DAMPs) are recognized by pattern recognition receptors (PRRs), activating the cyclic guanosine monophosphate-adenosine monophosphate synthase-stimulator of interferon genes (cGAS-STING) signaling pathway, a crucial component of the innate immune response to SARS-CoV-2. This pathway plays a dual role during infection. In the early phase of infection, the virus can suppress cGAS-STING signaling to evade immune detection. However, in the late stages, activation of this pathway can lead to excessive inflammation and tissue damage, exacerbating disease severity. Modulating the cGAS-STING pathway, whether through agonists like dimeric amidobenzimidazole (diABZI) or inhibitors targeting viral proteins, such as 3CLpro, for example, offers a promising personalized therapeutic to control the immune response and reduce severe inflammation, improving clinical outcomes in patients with severe COVID-19.